These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30555156)

  • 1. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
    Nardone A; Weir H; Delpuech O; Brown H; De Angelis C; Cataldo ML; Fu X; Shea MJ; Mitchell T; Veeraraghavan J; Nagi C; Pilling M; Rimawi MF; Trivedi M; Hilsenbeck SG; Chamness GC; Jeselsohn R; Osborne CK; Schiff R
    Br J Cancer; 2019 Feb; 120(3):331-339. PubMed ID: 30555156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER
    Robertson JFR; Evans A; Henschen S; Kirwan CC; Jahan A; Kenny LM; Dixon JM; Schmid P; Kothari A; Mohamed O; Fasching PA; Cheung KL; Wuerstlein R; Carroll D; Klinowska T; Lindemann JPO; MacDonald A; Mather R; Maudsley R; Moschetta M; Nikolaou M; Roudier MP; Sarvotham T; Schiavon G; Zhou D; Zhou L; Harbeck N
    Clin Cancer Res; 2020 Aug; 26(16):4242-4249. PubMed ID: 32234755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
    Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
    Guan J; Zhou W; Hafner M; Blake RA; Chalouni C; Chen IP; De Bruyn T; Giltnane JM; Hartman SJ; Heidersbach A; Houtman R; Ingalla E; Kategaya L; Kleinheinz T; Li J; Martin SE; Modrusan Z; Nannini M; Oeh J; Ubhayakar S; Wang X; Wertz IE; Young A; Yu M; Sampath D; Hager JH; Friedman LS; Daemen A; Metcalfe C
    Cell; 2019 Aug; 178(4):949-963.e18. PubMed ID: 31353221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER
    Hamilton EP; Patel MR; Armstrong AC; Baird RD; Jhaveri K; Hoch M; Klinowska T; Lindemann JPO; Morgan SR; Schiavon G; Weir HM; Im SA
    Clin Cancer Res; 2018 Aug; 24(15):3510-3518. PubMed ID: 29440181
    [No Abstract]   [Full Text] [Related]  

  • 15. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
    Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
    Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
    Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
    Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
    Borley AC; Hiscox S; Gee J; Smith C; Shaw V; Barrett-Lee P; Nicholson RI
    Breast Cancer Res; 2008; 10(6):R103. PubMed ID: 19055788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
    McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
    Simigdala N; Pancholi S; Ribas R; Folkerd E; Liccardi G; Nikitorowicz-Buniak J; Johnston SR; Dowsett M; Martin LA
    Br J Cancer; 2018 Aug; 119(3):313-322. PubMed ID: 29991699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.